Treatment patterns and attrition in metastatic renal cell carcinoma: real-life experience from the Turkish oncology group kidney cancer consortium (TKCC) database

Basit Öğe Kaydı
dc.authorscopusidİrfan Çiçin / 8922379100
dc.authorwosidİrfan Çiçin / JQU-1347-2023
dc.contributor.authorBölek, Hatice
dc.contributor.authorSertesen, Elif
dc.contributor.authorKuzu, Ömer Faruk
dc.contributor.authorTural, Deniz
dc.contributor.authorSim, Saadet
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorUçar, Gökhan
dc.contributor.authorIşık, Selver
dc.contributor.authorHacıoğlu, Bekir
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorArslan, Çağatay
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorKaraçin, Cengiz
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÖzgüroğlu, Mustafa
dc.contributor.authorYekedüz, Emre
dc.contributor.authorÜrün, Yüksel
dc.date.accessioned2025-04-16T13:43:06Z
dc.date.available2025-04-16T13:43:06Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractThe inclusion of patients with more favorable prognoses in clinical trials imits generalizability to broader and more diverse patient group. This study examines treatment patterns and attrition rates in Turkish oncology clinics for metastatic renal cell carcinoma. The percentages of patients receiving treatment in the second, third, and fourth lines of therapy were 62.8%, 27.4%, and 8.9%, respectively. Disease progression was the primary cause of attrition, followed by toxicity. Introduction: Despite the rapid evolution in management of metastatic renal cell carcinoma (mRCC) over the past decade, challenges remain in accessing new therapies in some parts of the world. Despite therapeutic advancements, attrition rates remain persistently high. This study aims to assess the treatment patterns and attrition rates of patients with mRCC in oncology clinics across Turkey. Patients and Methods: Patients diagnosed with mRCC between January 1, 2008, and December 31, 2022, with first-line systemic treatment data, were retrospectively evaluated using the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Results: The final analysis included a total of 1126 patients. The percentages of patients treated in the 2nd, 3rd, 4th, and 5th lines of therapy were 62.8%, 27.4%, 8.9%, and 2.1%, respectively. The drugs that were most commonly used in the groups were tyrosine kinase inhibitors (TKIs) (52.2%) and interferon (IFN)-alpha (43.3%) for the first line, TKIs (66.3%) and immunotherapy (IO) monotherapy (25.9%) for the second line, TKI (41.4%) and mTOR inhibitors (28.8%) for the third line, TKI (44.4%) and mTOR inhibitors (29%) for the fourth line, and IO monotherapy (37.5%) and TKI (25%) for the fifth line. For the first-line treatment, the primary cause of attrition was disease progression (66.4%), followed by toxicity (16.5%), death (11.2%), and patient preference (5.9%). The primary reason for attrition across all treatment lines was disease progression. Over time, the use of TKIs in first-line treatment increased, while IFN-alpha usage declined. IOs began to be utilized in earlier lines, predominantly in second-line treatment, though use of IO-based combination therapies remains limited. Conclusion: This study underscores that despite significant progress in therapeutic options, the adoption of novel agents remains slow, and attrition rates are still high. These findings indicate a disparity in systemic therapy compared to developed countries.
dc.identifier.citationBölek, H., Sertesen, E., Kuzu, O. F., Tural, D., Sim, S., Şendur, M. A. N., ... & Ürün, Y. (2025). Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. Clinical Genitourinary Cancer, 23(1), 102282.
dc.identifier.doi10.1016/dge.2024.102282
dc.identifier.endpage8
dc.identifier.issn1558-7673
dc.identifier.issn1938-0682
dc.identifier.issue1
dc.identifier.pmid39709686
dc.identifier.startpage1
dc.identifier.urihttp://dx.doi.org/10.1016/dge.2024.102282
dc.identifier.urihttps://hdl.handle.net/20.500.12713/6033
dc.identifier.volume23
dc.identifier.wosWOS:001396033200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorÇiçin, İrfan
dc.institutionauthoridİrfan Çiçin / 0000-0002-7584-3868
dc.language.isoen
dc.publisherCIG media group
dc.relation.ispartofClinical genitourinary cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectImmunotherapy
dc.subjectReal World Data
dc.subjectTyrosine Kinase Inhibitor
dc.subjectTargated Therapies
dc.subjectTreatment Patterns
dc.titleTreatment patterns and attrition in metastatic renal cell carcinoma: real-life experience from the Turkish oncology group kidney cancer consortium (TKCC) database
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1-s2.0-S1558767324002520-main.pdf
Boyut:
784.68 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu